SynthesisArchives of dermatological research2025
Trichoblastic carcinoma: a systematic review of an aggressive follicular neoplasm with an emphasis on Mohs micrographic surgery in management.
Synthesis in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichoblastic carcinoma (TC) is a rare and aggressive adnexal tumor with a high potential for metastasis and frequent misdiagnosis due to its histopathologic similarity to basal cell carcinoma (BCC). This systematic review consolidates current knowledge on TC, including its clinical presentation, histopathology, treatment approaches, and outcomes. TC most commonly presents on the face and scalp as a nodular lesion, often with ulceration. Histologically, it is characterized by basaloid islands, nuclear palisading, and high mitotic activity. Differentiating TC from BCC is crucial, as TC exhibits a significantly higher metastatic potential. Surgical excision remains the primary treatment, with Mohs micrographic surgery offering better recurrence-free outcomes. Emerging therapies, including targeted treatments and immunotherapy, have shown potential in select cases. However, due to the lack of standardized management guidelines, further research is needed to refine diagnostic criteria, optimize treatment strategies, and improve patient outcomes.
Indexed as
Identifiers
40413695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.